Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 3
2019 1
2020 2
2021 3
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Discovery of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic approach for Alzheimer's disease.
Du Y, Bradshaw WJ, Leisner TM, Annor-Gyamfi JK, Qian K, Bashore FM, Sikdar A, Nwogbo FO, Ivanov AA, Frye SV, Gileadi O, Brennan PE, Levey AI; Emory-Sage-SGC TREAT-AD Center; Axtman AD, Pearce KH, Fu H, Katis VL. Du Y, et al. Among authors: annor gyamfi jk. J Biol Chem. 2023 Dec;299(12):105382. doi: 10.1016/j.jbc.2023.105382. Epub 2023 Oct 21. J Biol Chem. 2023. PMID: 37866628 Free PMC article.
AD Informer Set: Chemical tools to facilitate Alzheimer's disease drug discovery.
Potjewyd FM, Annor-Gyamfi JK, Aubé J, Chu S, Conlon IL, Frankowski KJ, Guduru SKR, Hardy BP, Hopkins MD, Kinoshita C, Kireev DB, Mason ER, Moerk CT, Nwogbo F, Pearce KH, Richardson TI, Rogers DA, Soni DM, Stashko M, Wang X, Wells C, Willson TM, Frye SV, Young JE, Axtman AD. Potjewyd FM, et al. Among authors: annor gyamfi jk. Alzheimers Dement (N Y). 2022 Apr 20;8(1):e12246. doi: 10.1002/trc2.12246. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 35475262 Free PMC article.
Use of AD Informer Set compounds to explore validity of novel targets in Alzheimer's disease pathology.
Potjewyd FM, Annor-Gyamfi JK, Aubé J, Chu S, Conlon IL, Frankowski KJ, Guduru SKR, Hardy BP, Hopkins MD, Kinoshita C, Kireev DB, Mason ER, Moerk CT, Nwogbo F, Pearce KH Jr, Richardson TI, Rogers DA, Soni DM, Stashko M, Wang X, Wells C, Willson TM, Frye SV, Young JE, Axtman AD. Potjewyd FM, et al. Among authors: annor gyamfi jk. Alzheimers Dement (N Y). 2022 Apr 12;8(1):e12253. doi: 10.1002/trc2.12253. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 35434254 Free PMC article.
Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer's disease.
Du Y, Bradshaw WJ, Leisner TM, Annor-Gyamfi JK, Qian K, Bashore FM, Sikdar A, Nwogbo FO, Ivanov AA, Frye SV, Gileadi O, Brennan PE, Levey AI; Emory-Sage-SGC TREAT-AD Center; Axtman AD, Pearce KH, Fu H, Katis VL. Du Y, et al. Among authors: annor gyamfi jk. bioRxiv [Preprint]. 2023 May 22:2023.05.22.541727. doi: 10.1101/2023.05.22.541727. bioRxiv. 2023. PMID: 37292860 Free PMC article. Updated. Preprint.
12 results